Pancreatic Endocrine Tumors malady

Wikipedia: Neuroendocrine tumors (NETs) are neoplasms that arise from cells of the endocrine (hormonal) and nervous...⁴⁴ more...

MalaCards: Pancreatic Endocrine Tumors, also known as islet cell tumor, is related to pancreatic islet cell tumors and hypoglycemia. An important gene associated with Pancreatic Endocrine Tumors is ST11 (suppression of tumorigenicity 11 (pancreas)), and among its related pathways are Cellular responses to stress and Class A/1 (Rhodopsin-like receptors). The compounds 111in-pentetreotide and acth have been mentioned in the context of this disorder. Affiliated tissues include liver, lung and pancreas, and related mouse phenotypes are respiratory system and craniofacial.

pancreatic endocrine tumors 7 33 islet cell tumor 43

Diseases related to pancreatic endocrine tumors by text searches and GeneDecks gene sharing:

(show top 50)    (show all 624)

id	Related Disease	Score	Top Affiliating Genes
1	pancreatic islet cell tumors	35.7	SST, AFP, GAST
2	hypoglycemia	33.6	PCSK1, GCG, CHGA, CDKN3, MLN, MEN1
3	cushing's syndrome	30.1	CHGA, MEN1, CALCA, GHRH, SST, SYP
4	wdha syndrome	30.1	VIP, CALCA, SST, NF1
5	neurofibromatosis	29.8	VHL, MEN1, SST, NF1, TSC1, TSC2
6	somatostatinoma	29.7	GCG, VIP, CHGA, MEN1, CALCA, GHRH
7	zollinger-ellison syndrome	29.7	CHGA, CDH1, MLN, MEN1, GRP, GHRH
8	glucagonoma	29.2	PCSK2, PCSK1, GCG, VIP, CHGB, CHGA
9	hypercalcemia	28.6	CHGA, MEN1, CASR, CALCA, EGFR, TGFA
10	leydig cell tumor	28.5	ESR1, TP53, KRT7, SYP, AFP
11	acromegaly	27.8	GCG, VIP, CHGA, CDKN1B, MLN, MEN1
12	tuberous sclerosis	27.2	VHL, CDKN1B, CDKN3, ESR1, TP53, SST
13	von hippel-lindau disease	27.2	VIP, VHL, RARB, CHGA, MEN1, CA9
14	multiple endocrine neoplasia	27.2	GCG, VIP, VHL, CHGB, CHGA, CDKN2C
15	burkitt's lymphoma	26.5	BCL2, CDKN1B, CDKN2A, CDK4, MGMT, CASP3
16	renal cell carcinoma	25.8	VHL, VEGFC, RARB, CEACAM1, CDKN1B, CDH1
17	insulinoma	25.6	PCSK2, PCSK1, GCG, VIP, CHGA, CDKN1B
18	carcinoid tumors	23.8	PCSK2, PCSK1, GCG, VIP, BCL2, CHGB
19	pheochromocytoma	22.2	PCSK2, PCSK1, VIP, VHL, BCL2, CHGB
20	pancreatitis	21.3	NCALD, PCSK2, PCSK1, GCG, SELE, SEMA3C
21	thyroiditis	16.0	PCSK2, PCSK1, GCG, SELE, VIP, VHL
22	carcinoma	14.5	PCSK2, GCG, SELE, VIP, VHL, VEGFC
23	oncogenic osteomalacia	13.9	CALCA, SSTR1, SSTR2, SSTR3, SSTR5
24	paraurethral gland neoplasm	13.8	CDX2, KRT7, KRT20
25	bladder adenocarcinoma	13.8	CDX2, KRT7, KRT20
26	fetal adenoma	13.8	GHRH, SSTR2, SSTR5
27	maturity-onset diabetes of the young	13.8	GCG, ISL1, PDX1, HES1, NEUROD1, NEUROG3
28	signet ring cell adenocarcinoma	13.8	CDX2, KRT7, KRT20
29	papillary serous adenocarcinoma	13.8	KRT7, KRT20, NKX2-1
30	familial isolated hyperparathyroidism	13.7	MEN1, CASR, GAST
31	esthesioneuroblastoma	13.7	ASCL1, SST, SSTR2, SYP
32	adenomatoid tumor	13.7	CEACAM5, CEACAM1, KRT7, NKX2-1
33	ampulla of vater adenocarcinoma	13.7	CDX2, KRT7, KRT20
34	intestinal neuroendocrine tumor	13.7	CHGA, CDX2, SST
35	growth hormone secreting pituitary adenoma	13.7	MEN1, SST, SSTR2, SSTR5
36	dumping syndrome	13.7	GCG, MLN, SST, NTS
37	osteomalacia	13.7	MEN1, CASR, CALCA, SSTR1, SSTR2, SSTR3
38	carney complex	13.7	VHL, CHGA, CDKN1B, MEN1, SYP
39	angiomatosis	13.7	VHL, DLK1, TSC2
40	ewing's family of tumors	13.7	CHGA, CDK4, GRP, SYP
41	subependymal giant cell astrocytoma	13.6	TSC1, TSC2, SYP
42	pancreatic cholera	13.6	VIP, SST, GAST
43	apudoma	13.6	CALCA, SST, GAST
44	primary hyperparathyroidism	13.6	CHGA, MEN1, CASR, CALCA, GAST
45	sex cord-gonadal stromal tumor	13.6	CEACAM5, KRT7, NPY, NKX2-1
46	atrophic gastritis	13.6	CHGA, CDX2, MEN1, SST, GAST
47	duodenum cancer	13.6	MEN1, SST, GAST
48	thyroid cancer	13.6	CALCA, KRT20, KRT19, NKX2-1
49	mucinous cystadenocarcinoma	13.6	SMAD4, KRT7, KRT20
50	merkel cell carcinoma	13.6	CHGA, SST, KRT20, SYP, NKX2-1

Approved drugs:

Drug clinical trials:

MalaCards organs/tissues related to pancreatic endocrine tumors:

²²

MGI Mouse Phenotypes related to pancreatic endocrine tumors:

²⁵ (show all 29)

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	respiratory system phenotype	MP:0005388	9.9	UTRN, ASCL1, FBN1, CALCA, SSTR4, NF1
2	craniofacial phenotype	MP:0005382	9.8	EGLN3, HES1, POU3F4, EGLN2, NF1, NOTCH1
3	endocrine/exocrine gland phenotype	MP:0005379	9.7	AFP, PCSK2, PCSK1, CDKN2C, CDKN1B, CDX2
4	other phenotype	MP:0005395	8.7	DLK1, PTGS2, CASR, MAP2K4, FBN1, CDKN2A
5	hematopoietic system phenotype	MP:0005397	8.5	SSTR4, SMAD4, NOTCH1, NF1, EGLN1, EGLN3
6	normal phenotype	MP:0002873	8.4	VIP, SLC18A1, NPY, SYP, TSC2, NEUROG3
7	embryogenesis phenotype	MP:0005380	8.2	NF1, CTNNB1, CDK4, FBN1, ISL1, NOTCH1
8	liver/biliary system phenotype	MP:0005370	8.1	VHL, UTRN, MEN1, MAP2K4, GHRH, TP53
9	immune system phenotype	MP:0005387	8.0	THBS1, LYVE1, GAST, TYK2, HES1, PCSK1
10	reproductive system phenotype	MP:0005389	7.7	S100A11, CDKN2C, CDKN1B, CDX2, CDH1, MEN1
11	limbs/digits/tail phenotype	MP:0005371	7.6	ESR1, FBN1, CDX2, UTRN, NF1, ISL1
12	nervous system phenotype	MP:0003631	7.5	CDKN2C, CDKN1B, CDK4, FGF13, MEN1, FBN1
13	behavior/neurological phenotype	MP:0005386	7.4	MAP2K4, CACNA1G, CASR, CALCA, SST, SSTR1
14	hearing/vestibular/ear phenotype	MP:0005377	7.4	NEUROD1, BCL2, CDKN1B, CASP3, CALCA, DDR1
15	pigmentation phenotype	MP:0001186	6.8	FBN1, CDKN2A, CDKN1B, BCL2, SEMA3C, ASCL1
16	adipose tissue phenotype	MP:0005375	6.6	ESR1, FBN1, CDKN1B, BCL2, PCSK1, DLK1
17	integument phenotype	MP:0010771	6.5	VHL, BCL2, CDKN2C, CDKN1B, CDH5, CDK4
18	no phenotypic analysis	MP:0003012	6.4	SST, SSTR3, PTGS2, TP53, ESR1, CACNA1G
19	renal/urinary system phenotype	MP:0005367	6.0	NOTCH1, NF1, EGFR, EGLN1, HIF1A, TSC1
20	skeleton phenotype	MP:0005390	5.4	VHL, DDR1, CTNNB1, NOTCH1, KRT19, EGFR
21	mortality/aging	MP:0010768	5.2	EGLN3, HES1, TYK2, TSC1, TSC2, TIMP3
22	digestive/alimentary phenotype	MP:0005381	5.1	CDX2, CDH1, ISL1, MEN1, CASP3, CA9
23	vision/eye phenotype	MP:0005391	5.0	HIF1A, TIMP3, HES1, EGLN3, EGFR, THBS1
24	tumorigenesis	MP:0002006	4.4	THBS1, PRDX1, NKX2-1, AFP, GAST, CDK4
25	muscle phenotype	MP:0005369	4.4	PCSK1, VHL, RARB, UTRN, BCL2, CDKN1B
26	growth/size phenotype	MP:0005378	3.8	TIMP3, THBS1, TGFA, NPY, SLC18A2, NKX2-1
27	cellular phenotype	MP:0005384	2.9	MEN1, FBN1, MAP2K4, CASP3, CASR, ESR1
28	cardiovascular system phenotype	MP:0005385	2.8	FBN1, MEN1, ISL1, CDH1, CDK4, CDX2
29	homeostasis/metabolism phenotype	MP:0005376	1.6	TSC1, TSC2, TIMP3, THBS1, PRDX2, PRDX1

Articles related to pancreatic endocrine tumors:

(show top 50)    (show all 58)

id	Title	Authors	Year	Affiliating Genes
1	MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast m ajority of cases. (20566584)	Corbo V.... Scarpa A.	2010	MEN1
2	Cleaved caspase-3 immunocytochemical staining for pan creatic islets and pancreatic endocrine tumors: A potential marker for biologic al malignancy. (21099299)	Tomita T.	2010	CASP3
3	Immunohistochemical and clinicopathological correlati on of the metastasis-associated gene 1 (MTA1) expression in benign and malignan t pancreatic endocrine tumors. (19377441)	Hofer M.D.... NosAc V.	2009	MTA1
4	Heterogeneity of tumor prognostic markers: a reproducibility study applied to liver metastases of pancreatic endocrine tumors. (18997736)	Couvelard A.... Ruszniewski P.	2009	SSTR2
5	Neurogenin 3 and neurogenic differentiation 1 are retained in the cytoplasm of multiple endocrine neoplasia type 1 islet and pancreatic endocrine tumor cells. (19307926)	Lejonklou M.H.... Skogseid B.	2009	NEUROD1, RPL10, PDX1
6	Proliferative rate in endoscopic ultrasound fine-needle aspiration of pancreatic endocrine tumors: correlation with clinical behavior. (19347828)	Alexiev B.A.... Ioffe O.B.	2009	MKI67
7	VHL inactivation is an important pathway for the deve lopment of malignant sporadic pancreatic endocrine tumors. (19690016)	Schmitt A.M.... Perren A.	2009	HIF1A, CA9, VHL
8	Expression pattern and functional relevance of epidermal growth factor receptor and cyclooxygenase-2: novel chemotherapeutic targets in pancreatic endocrine tumors? (19098866)	Bergmann F.... Kern M.A.	2009	EGFR
9	Pancreatic endocrine tumors-c-erb B2 (Her-2/neu), bcl-2, and p-53 immunohistochemical testing and their value in assessing prognosis. (18091321)	Proca D.M.... Frankel W.L.	2008	BCL2
10	Loss of membrane localization and aberrant nuclear E-cadherin expression correlates with invasion in pancreatic endocrine tumors. (18300809)	Chetty R.... Asa S.L.	2008	CDH1, CTNNB1
11	Overexpression of the oxygen sensors PHD-1, PHD-2, PHD-3, and FIH Is associated with tumor aggressiveness in pancreatic endocrine tumors. (18927305)	Couvelard A.... Bedossa P.	2008	EGLN1, EGLN2, EGLN3
12	Islet 1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases. (18300808)	Schmitt A.M.... Perren A.	2008	CDX2, ISL1
13	Lack of nuclear expression of hairy and enhancer of split-1 (HES1) in pancreatic endocrine tumors. (18491256)	Johansson T.... Skogseid B.	2008	NOTCH1, ASCL1, HES1
14	Mutational analysis of p27 (CDKN1B) and p18 (CDKN2C) in sporadic pancreatic endocrine tumors argues against tumor-suppressor function. (17710155)	Lindberg D.... Westin G.	2007	CDKN1B, MEN1, CDKN2C
15	Lymphatic vessel endothelial hyaluronan receptor 1 immunocytochemical staining for pancreatic islets and pancreatic endocrine tumors. (18090227)	Tomita T.	2007	LYVE1
16	Clinicopathologic and immunohistochemical correlation in sporadic pancreatic endocrine tumors: possible roles of utrophin and cyclin D1 in malignant progression. (17306326)	Chang M.C.... Nose V.	2007	UTRN
17	A malignant nonfunctioning pancreatic endocrine tumor with a unique pattern of intraductal growth. (17520210)	Inagaki M.... Kasai S.	2007	VIP
18	Proteomic analysis of pancreatic endocrine tumor cell lines treated with the histone deacetylase inhibitor trichostatin A. (17443844)	Cecconi D.... Righetti P.G.	2007	PRDX2, PRDX1, S100A11
19	WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors. (18059224)	Schmitt A.M.... Perren A.	2007	KRT19
20	Cyclin-dependent kinase 4 (CDK4) expression in pancreatic endocrine tumors. (17664862)	Lindberg D.... Westin G.	2007	CDK4
21	Identification of potential therapeutic targets by gene-expression profiling in pancreatic endocrine tumors. (17064702)	Couvelard A.... Pezzella F.	2006	CDH5, TYK2, MAP2K4
22	Pancreatic endocrine tumors are a rare manifestation of the neurofibromatosis type 1 phenotype: molecular analysis of a malignant insulinoma in a NF-1 patient. (16861979)	Perren A.... Komminoth P.	2006	NF1
23	Current advances in the diagnosis and treatment of pancreatic endocrine tumors. (15608508)	Viola K.V.... Sosa J.A.	2005	EGFR
24	Spindle cell pancreatic endocrine tumor associated with Cushing's syndrome. (16199900)	Chetty R.... Serra S.	2005	SYP
25	Expression of lymphangiogenic factors and evidence of intratumoral lymphangiogenesis in pancreatic endocrine tumors. (15466385)	Sipos B.... KlAPppel G.	2004	VEGFC
26	Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors. (15053236)	Panzuto F.... Delle Fave G.	2004	CHGA
27	Frequent methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene in pancreatic endocrine tumors. (12629131)	Wild A.... Bartsch D.K.	2003	TIMP3
28	CpG island methylation in carcinoid and pancreatic endocrine tumors. (12584572)	Chan A.O.... Rashid A.	2003	ESR1, PTGS2, RARB
29	DPC4/Smad4: no mutations, rare allelic imbalances, and retained protein expression in pancreatic endocrine tumors. (14639103)	Perren A.... Komminoth P.	2003	SMAD4
30	Expression of the two isoforms of the vesicular monoamine transporter (VMAT1 and VMAT2) in the endocrine pancreas and pancreatic endocrine tumors. (12871984)	Anlauf M.... Weihe E.	2003	SLC18A2, SLC18A1
31	Malignant pancreatic endocrine tumor in a child with tuberous sclerosis. (14508401)	Francalanci P.... Boldrini R.	2003	TSC1, TSC2
32	A calcitonin and vasoactive intestinal peptide-producing pancreatic endocrine tumor associated with the WDHA syndrome. (14716055)	Ichimura T.... Katoh H.	2003	CALCA, VIP
33	Ductal and acinar differentiation in pancreatic endocrine tumors. (12395898)	Kamisawa T.... Yamaguchi T.	2002	TP53, CEACAM5
34	Expression of somatostatin receptor and effects of somatostatin analog on pancreatic endocrine tumors. (12181718)	Oda Y.... Funahashi H.	2002	SST, SSTR1
35	Anomalous overexpression of p27(Kip1) in sporadic pancreatic endocrine tumors. (11266285)	Guo S.S.... Sawicki M.P.	2001	CDKN1B
36	Cytokeratin 7 and 20 and thyroid transcription factor 1 can help distinguish pulmonary from gastrointestinal carcinoid and pancreatic endocrine tumors. (11679943)	Cai Y.C.... Odze R.D.	2001	KRT7, KRT20, NKX2-1
37	Immunohistochemical expression of chromogranins A and B, prohormone convertases 2 and 3, and amidating enzyme in carcinoid tumors and pancreatic endocrine tumors. (10697270)	Kimura N.... Aunis D.	2000	PCSK1, PCSK2, CHGA
38	Pancreatic endocrine tumor--from clinic to calcium sensing receptor (10976408)	Imamura M.	2000	CASR
39	Genetic alterations on 3p, 11q13, and 18q in nonfamilial and MEN 1-associated pancreatic endocrine tumors. (10502325)	Hessman O.... Skogseid B.	1999	MEN1
40	Pancreatic endocrine tumors: recent advances. (10436815)	Jensen R.T.	1999	GHRH
41	Cellular composition and anatomic distribution in nonfunctioning pancreatic endocrine tumors: immunohistochemical study of 30 cases. (10374408)	Zheng X.... Shen K.	1998	GAST
42	Pancreatic endocrine tumor with signet ring cell features: a case report with novel ultrastructural observations. (9615384)	Stokes M.B.... Melamed J.	1998	SYP
43	Mutation of the MENIN gene in sporadic pancreatic endocrine tumors. (9766672)	Wang E.H.... Sawicki M.P.	1998	MEN1
44	A novel pancreatic endocrine tumor suppressor gene locus on chromosome 3p with clinical prognostic implications. (9218518)	Chung D.C.... Arnold A.	1997	VHL, ST11
45	Lack of p53 immunoreactivity in pancreatic endocrine tumors. (8743819)	Lee C.S.	1996	TP53
46	Immunolocalization of neuropeptide Y in human pancreatic endocrine tumors. (7479336)	Waeber G.... Grouzmann E.	1995	NPY
47	Glucagon-like peptide 1 immunoreactivity in gastroentero-pancreatic endocrine tumors: a light- and electron-microscopic study. (8062345)	Eissele R.... GAPke B.	1994	GCG
48	Glucagon-like peptide-1 (GLP-1) molecular forms in human pancreatic endocrine tumors resemble those in intestine rather than pancreas. (7835211)	Tateishi K.... Matsuoka Y.	1994	GCG
49	Coexpression of insulin and somatostatin in single secretory granules of a pancreatic endocrine tumor. (8102485)	Leone B.E.... Taccagni G.L.	1993	SST
50	Islet amyloid polypeptide and calcitonin gene-related peptide immunoreactivity in amyloid and tumor cells of canine pancreatic endocrine tumors. (1972303)	O'Brien T.D.... Johnson K.H.	1990	CALCA

Genes related to pancreatic endocrine tumors according to GeneCards:

(show top 50)    (show all 90)

id	Symbol	Description	Score	GeneCards Section Context
1	ST11	suppression of tumorigenicity 11 (pancreas)	11.0	Publications
2	POU3F4	POU class 3 homeobox 4	11.0	Publications
3	EGLN2	egl nine homolog 2 (C. elegans)	11.0	Publications
4	SSTR4	somatostatin receptor 4	11.0	Publications
5	S100A11	S100 calcium binding protein A11	11.0	Publications
6	SSTR1	somatostatin receptor 1	11.0	Publications
7	NEUROG3	neurogenin 3	11.0	Publications
8	ISL1	ISL LIM homeobox 1	11.0	Publications
9	RPL10	ribosomal protein L10	11.0	Publications
10	EGLN3	egl nine homolog 3 (C. elegans)	11.0	Publications
11	SSTR3	somatostatin receptor 3	11.0	Publications
12	ASCL1	achaete-scute complex homolog 1 (Drosophila)	11.0	Publications
13	HIF1AN	hypoxia inducible factor 1, alpha subunit inhibitor	11.0	Publications
14	CHGB	chromogranin B (secretogranin 1)	11.0	Publications
15	MEN1	multiple endocrine neoplasia I	11.0	Publications
16	DLK1	delta-like 1 homolog (Drosophila)	11.0	Publications
17	HES1	hairy and enhancer of split 1, (Drosophila)	11.0	Publications
18	LYVE1	lymphatic vessel endothelial hyaluronan receptor 1	11.0	Publications
19	PRDX1	peroxiredoxin 1	11.0	Publications
20	SLC18A1	solute carrier family 18 (vesicular monoamine), member 1	11.0	Publications
21	MLN	motilin	11.0	Publications
22	PRDX2	peroxiredoxin 2	11.0	Publications
23	SSTR2	somatostatin receptor 2	11.0	Publications
24	NEUROD1	neuronal differentiation 1	11.0	Publications
25	CEACAM1	carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein)	11.0	Publications
26	CDKN2C	cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4)	11.0	Publications
27	SSTR5	somatostatin receptor 5	11.0	Publications
28	CACNA1G	calcium channel, voltage-dependent, T type, alpha 1G subunit	11.0	Publications
29	PCSK1	proprotein convertase subtilisin/kexin type 1	11.0	Publications
30	NTS	neurotensin	11.0	Publications
31	TYK2	tyrosine kinase 2	11.0	Publications
32	PDX1	pancreatic and duodenal homeobox 1	11.0	Publications
33	NKX2-1	NK2 homeobox 1	11.0	Publications
34	CA9	carbonic anhydrase IX	11.0	Publications
35	MTA1	metastasis associated 1	11.0	Publications
36	TIMP3	TIMP metallopeptidase inhibitor 3	11.0	Publications
37	DDR1	discoidin domain receptor tyrosine kinase 1	11.0	Publications
38	EGLN1	egl nine homolog 1 (C. elegans)	11.0	Publications
39	SLC18A2	solute carrier family 18 (vesicular monoamine), member 2	11.0	Publications
40	SYP	synaptophysin	11.0	Publications
41	CDX2	caudal type homeobox 2	11.0	Publications
42	GHRH	growth hormone releasing hormone	11.0	Publications
43	CDH5	cadherin 5, type 2 (vascular endothelium)	11.0	Publications
44	VIP	vasoactive intestinal peptide	11.0	Publications
45	TSC1	tuberous sclerosis 1	11.0	Publications
46	VHL	von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase	11.0	Publications
47	SEMA3C	sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3C	11.0	Publications
48	KRT20	keratin 20	11.0	Publications
49	CHGA	chromogranin A (parathyroid secretory protein 1)	11.0	Publications
50	KRT7	keratin 7	11.0	Publications

Pathways related to pancreatic endocrine tumors according to GeneDecks:

(show top 50)    (show all 66)

id	Pathway	Score	Top Affiliating Genes
1	Cellular responses to stress38	10.7	HIF1AN, EGLN1, CA9, EGLN2, EGLN3, VHL
2	Class A/1 (Rhodopsin-like receptors)38	10.5	SSTR5, SSTR4, SSTR3, SSTR2, SSTR1, NPY
3	Signal transduction_PTEN pathway41	10.3	TSC2
4	Akt Signaling36	10.3	DDR1, TSC1, TSC2, TIMP3, FGF13, VEGFC
5	Renal cell carcinoma20	10.1	TGFA, HIF1A, EGLN3, EGLN1, VHL, EGLN2
6	Signal transduction PTEN pathway10	10.1	TSC2, CASP3
7	14-3-3 Induced Intracellular Signaling36	10.1	TIMP3, TSC2, TSC1, GHRH, MAP2K4, FGF13
8	Transcription factors in neurogenesis10	10.1	HES1, POU3F4, NEUROD1, NEUROG3, ASCL1
9	Non-small cell lung cancer20	10.0	TGFA, CDKN2A, CDK4
10	Transcription P53 signaling pathway10	9.8	MAP2K4, TP53, CDKN2A
11	JNK Pathway36	9.7	TP53, FGF13, BCL2, GHRH
12	mTOR Pathway36	9.7	TSC2, GHRH, TGFA, HIF1A, TSC1, VEGFC
13	G1-S Phase Transition36	9.6	CDKN1B, CDK4, CDKN2C, CDKN2A, TP53
14	Celecoxib Pathway, Pharmacodynamics34	9.4	PTGS2, CTNNB1, CA9, CASP3, CACNA1G, CDKN1B
15	HIF1Alpha Pathway36	9.4	HIF1A, HIF1AN, VHL, EGLN1, TP53, CDKN2A
16	p53 signaling pathway20	9.2	CDKN2A, CDK4, CASP3, TP53, TSC2, THBS1
17	Presenilin-Mediated Signaling36	9.2	NOTCH1, CTNNB1, CACNA1G, CDH1, BCL2, CDH5
18	Breast Cancer Regulation by Stathmin136	9.2	FGF13, MAP2K4, GHRH, EGFR, TIMP3, TGFA
19	Selected targets of p5310	9.1	TP53, CDK4, MGMT, BCL2, THBS1
20	p53 Signaling36	9.1	BCL2, HIF1A, THBS1, CDK4, CASP3, TP53
21	Angiogenesis3	9.1	VHL, TGFA, CDH5, VEGFC, TIMP3, HIF1A
22	Nanog in Mammalian ESC Pluripotency36	8.9	TIMP3, DDR1, GHRH, CTNNB1, FGF13, EGFR
23	Small cell lung cancer20	8.8	CDK4, TP53, PTGS2, RARB, BCL2, CDKN1B
24	Apoptotic Pathways in Synovial Fibroblasts36	8.7	TIMP3, VEGFC, FGF13, TP53, EGFR, TGFA
25	Transcription_P53 signaling pathway41	8.7	CTNNB1, BCL2, CDKN2A, MAP2K4, TP53
26	GSK3 Signaling36	8.6	TIMP3, GHRH, FGF13, CDH1, CDH5, VEGFC
27	eNOS Signaling36	8.6	EGFR, DDR1, TGFA, GHRH, ESR1, CASP3
28	Melanoma20	8.6	CDKN2A, EGFR, TP53, CDK4, CDH1, FGF13
29	DHA Signaling36	8.6	FGF13, TIMP3, GHRH, CASP3, BCL2, VEGFC
30	ERK Signaling36	8.6	FBN1, FGF13, VEGFC, TGFA, EGFR, DDR1
31	JAK-STAT Pathway36	8.5	DDR1, GHRH, MAP2K4, FGF13, BCL2, VEGFC
32	Bladder cancer20	8.5	CDK4, VEGFC, CDKN2A, CDH1, TP53, EGFR
33	Renin-Angiotensin Pathway36	8.5	FGF13, VEGFC, TGFA, GHRH, MAP2K4, PTGS2
34	TGF-Beta Pathway36	8.5	EGFR, MAP2K4, FGF13, CDH1, TIMP3, BCL2
35	Telomerase Components in Cell Signaling36	8.4	FGF13, GHRH, TP53, EGFR, TIMP3, TGFA
36	Epithelial Adherens Junctions36	8.4	CTNNB1, EGFR, TIMP3, TGFA, NOTCH1, VEGFC
37	Glioblastoma Multiforme36	8.4	TSC2, TSC1, EGFR, NF1, TP53, MAP2K4
38	Rho Family GTPases36	8.2	VEGFC, BCL2, MAP2K4, DDR1, FGF13, FBN1
39	p53 Mediated Apoptosis36	8.1	BCL2, TGFA, TIMP3, EGFR, TP53, GHRH
40	Prostate cancer20	8.1	TGFA, CTNNB1, EGFR, BCL2, TP53, CDKN1B
41	Estrogen Pathway36	8.1	ESR1, BCL2, GHRH, VEGFC, DDR1, EGFR
42	PAK Pathway36	8.0	TGFA, TIMP3, EGFR, GHRH, CASP3, MAP2K4
43	MAPK Signaling36	7.9	TGFA, TIMP3, EGFR, TP53, GHRH, MAP2K4
44	Mitochondrial Apoptosis36	7.7	EGFR, BCL2, VEGFC, TGFA, TIMP3, TP53
45	Cellular Apoptosis Pathway36	7.7	BCL2, FGF13, CASP3, GHRH, TP53, EGFR
46	ILK Signaling36	7.7	HIF1A, EGFR, TGFA, CTNNB1, DDR1, GHRH
47	Colorectal Cancer Metastasis36	7.7	CTNNB1, MAP2K4, CDH1, PTGS2, CASP3, TP53
48	Pathways in cancer20	7.0	TP53, VEGFC, RARB, BCL2, CDK4, CDKN1B
49	Pancreatic Adenocarcinoma36	6.8	CDKN1B, CDKN2A, CDK4, FGF13, TP53, PTGS2
50	Molecular Mechanisms of Cancer36	6.0	CDH1, CDK4, CDKN2A, CDKN1B, CTNNB1, RARB

Compounds related to pancreatic endocrine tumors according to GeneDecks:

(show top 50)    (show all 268)

id	Compound	Score	Top Affiliating Genes
1	111in-pentetreotide32	10.1	CHGA, CALCA, SST, SSTR1, SSTR2, SSTR5
2	acth32	9.4	PCSK2, PCSK1, VIP, CEACAM1, MLN, GRP
3	gnrh32	9.2	PCSK1, GCG, MKI67, GRP, GHRH, CTNNB1
4	rapamycin32 42	10.2	GCG, VHL, CDK4, CA9, SST, NF1
5	oxyntomodulin32 42	10.2	PCSK2, PCSK1, GCG, VIP, CHGA, MLN
6	octreotide32 42 9 9	12.2	GCG, VIP, CHGA, MLN, MKI67, GRP
7	dopamine32 9 18 9	12.1	GCG, SELE, VIP, RARB, CHGB, CDKN2A
8	ribonucleic acid32	8.8	PCSK2, PCSK1, VEGFC, RARB, CHGA, CEACAM5
9	forskolin32 42 9 9	11.8	PCSK1, GCG, VIP, RARB, CHGA, CDKN1B
10	5-hydroxytryptamine32	8.7	GCG, VIP, CHGA, CDKN3, MLN, GRP
11	histamine32 18	9.4	GCG, SELE, VIP, CHGA, CDH5, CDH1
12	arginine32	8.4	PCSK2, PCSK1, GCG, VIP, RARB, UTRN
13	ly29400232	8.3	GCG, SELE, VHL, CDKN1B, CDKN3, CDH1
14	formaldehyde32 18	9.2	SELE, CHGA, CDKN1B, CDKN3, CDH1, MKI67
15	glycogen32 18	9.2	GCG, VHL, CHGA, CEACAM5, CEACAM1, CDKN1B
16	glucose32	8.1	PCSK2, PCSK1, GCG, VHL, VEGFC, CDH5
17	cyclic amp32 18	9.1	PCSK2, GCG, RARB, CHGA, CDKN1B, CDKN2A
18	matrigel32	8.1	SELE, VEGFC, CHGA, CEACAM1, CDH5, CDH1
19	oxygen32 18	8.8	BCL2, CDKN1B, CDKN2A, CDK4, FBN1, CASP3
20	agar32	7.8	RARB, CEACAM5, CDKN1B, CDKN2A, CDK4, CDH1
21	adenylate32	7.7	PCSK1, GCG, SELE, VIP, RARB, CHGA
22	vitamin d32	7.7	RARB, CHGA, CDX2, CDK4, CDH1, MEN1
23	alanine32	7.4	GCG, SELE, VIP, CEACAM1, CDKN1B, CDKN2A
24	wortmannin32 42	8.2	GCG, BCL2, CDKN1B, CDKN3, CDH1, GRP
25	lactate32	7.1	GCG, SELE, VIP, CHGA, CEACAM5, CDKN3
26	thymidine32 18	8.0	VIP, VEGFC, RARB, CEACAM5, CDKN1B, CDX2
27	calcium32 9 18 9	9.8	NCALD, PCSK2, PCSK1, VIP, VHL, VEGFC
28	gefitinib32 34 9 9	9.8	GCG, CEACAM5, CDKN1B, CDKN3, CDK4, CDH1
29	oligonucleotide32	6.6	VHL, VEGFC, RARB, BCL2, CHGB, CHGA
30	butyrate32	6.5	GCG, BCL2, CEACAM5, CDKN1B, CDKN2A, CDX2
31	phosphatidylinositol32	6.5	VHL, VEGFC, BCL2, CEACAM5, CEACAM1, CDKN1B
32	nitric oxide32 9 18 9	9.5	SELE, VIP, VHL, VEGFC, UTRN, CHGA
33	irinotecan32 34 9 9	9.4	CEACAM5, CDKN2A, CDH1, MKI67, MGMT, GRP
34	retinoic acid32 42 18	8.3	PCSK2, VEGFC, RARB, CHGA, CEACAM1, CDKN2A
35	pd 98,05932	6.3	GCG, VEGFC, BCL2, CDKN1B, CDK4, CDH1
36	tamoxifen32 34 9 9	9.2	SELE, BCL2, CHGA, MTA1, CDKN1B, CDH1
37	progesterone32 42 9 18 9	9.9	PCSK1, VEGFC, RARB, BCL2, CHGA, MTA1
38	testosterone32 9 18 9	8.9	SELE, VIP, VEGFC, RARB, CHGA, CDKN1B
39	dexamethasone32 42 34 9 9	9.8	PCSK2, VIP, VEGFC, RARB, BCL2, CHGB
40	paclitaxel32 34 9 9	8.2	BCL2, CHGA, CDKN1B, CDKN2A, CDK4, CDH1
41	5fluorouracil32	5.1	GCG, SELE, BCL2, CEACAM5, CDKN1B, CDKN2A
42	estrogen32	5.1	PCSK1, GCG, VIP, VHL, VEGFC, RARB
43	doxorubicin32 34 9 9	7.7	SELE, BCL2, CEACAM5, CDKN1B, CDKN2A, CDK4
44	cisplatin32 34 9 9	7.5	RARB, BCL2, CHGA, CEACAM5, CDKN1B, CDKN2A
45	genistein32 9 18 9	7.5	GCG, SELE, RARB, BCL2, CDKN1B, CDKN2A
46	cycloheximide32	4.3	GCG, SELE, RARB, BCL2, CHGA, CEACAM1
47	vegf32	4.0	GCG, SELE, VIP, VHL, VEGFC, BCL2
48	paraffin32	3.9	VEGFC, BCL2, CHGA, CEACAM5, CDKN1B, CDKN2A
49	tyrosine32	3.6	PCSK2, SEMA3C, VIP, VHL, VEGFC, RARB
50	serine32	3.0	PCSK2, PCSK1, GCG, SELE, VIP, VHL

Cellular components related to pancreatic endocrine tumors according to GeneDecks:

id	Name	GO ID	Score	Top Affiliating Genes
1	secretory granule	GO:030141	9.9	GCG, THBS1, PCSK2, PCSK1, CHGB, CHGA
2	extracellular region	GO:005576	8.5	VEGFC, THBS1, NOTCH1, NTS, SST, DDR1
3	protein complex	GO:043234	8.1	SYP, UTRN, CDKN2A, MEN1, TP53, PTGS2
4	extracellular space	GO:005615	7.6	VEGFC, TGFA, THBS1, EGFR, SST, DLK1
5	nucleoplasm	GO:005654	7.4	MEN1, SMAD4, ESR1, HIF1A, EGLN3, EGLN2
6	membrane	GO:016020	7.2	CTNNB1, EGFR, TYK2, TSC1, TSC2, SLC18A1
7	cytosol	GO:005829	6.9	CDKN1B, CDKN2C, BCL2, MAP2K4, VHL, NCALD
8	cytoplasm	GO:005737	4.3	RPL10, HES1, HIF1AN, HIF1A, TYK2, TSC1
9	nucleus	GO:005634	3.1	HES1, EGLN3, EGLN2, EGLN1, EGFR, KRT7

Biological processes related to pancreatic endocrine tumors according to GeneDecks:

(show all 40)

id	Name	GO ID	Score	Top Affiliating Genes
1	somatostatin signaling pathway	GO:038170	10.8	SSTR3, SSTR2, SSTR1, SSTR5, SSTR4
2	cellular response to glucocorticoid stimulus	GO:071385	10.7	SSTR5, SSTR3, SSTR2, ISL1
3	peptidyl-proline hydroxylation to 4-hydroxy-L-proline	GO:018401	10.7	EGLN3, EGLN2, EGLN1
4	G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	GO:007187	10.6	SSTR1, SSTR2, NPY, SSTR5, SSTR4, SSTR3
5	neurogenesis	GO:022008	10.6	RARB, NEUROD1, ASCL1, PCSK1
6	regulation of transcription from RNA polymerase II promoter in response to hypoxia	GO:061418	10.4	EGLN1, HIF1A, VHL, EGLN3, HIF1AN, CA9
7	endocrine pancreas development	GO:031018	10.3	PDX1, NEUROG3, NEUROD1, HES1
8	glucose homeostasis	GO:042593	10.3	SSTR5, PDX1, HIF1A, SLC18A2, NEUROD1
9	cellular response to stress	GO:033554	10.3	HIF1A, HIF1AN, EGLN3, EGLN1, KRT20, EGLN2
10	cell-cell signaling	GO:007267	10.3	PCSK1, MLN, FGF13, CALCA, GHRH, SST
11	outflow tract morphogenesis	GO:003151	10.3	SEMA3C, ISL1, HES1, HIF1A
12	feeding behavior	GO:007631	10.2	NPY, CALCA, GCG, NKX2-1
13	oligodendrocyte differentiation	GO:048709	10.1	NKX2-1, NOTCH1, BCL2, CDKN2C
14	cerebral cortex development	GO:021987	10.1	ASCL1, TSC1, HIF1A, NF1, NPY
15	negative regulation of oligodendrocyte differentiation	GO:048715	10.1	NF1, CTNNB1, NOTCH1, HES1
16	response to folic acid	GO:051593	10.0	TIMP3, BCL2, MGMT, ASCL1
17	negative regulation of cyclin-dependent protein kinase activity	GO:045736	10.0	CASP3, CDKN1B, CDKN2A, MEN1
18	regulation of cell-matrix adhesion	GO:001952	10.0	NF1, BCL2, TSC1
19	cellular response to organic substance	GO:071310	10.0	TIMP3, SYP, CASP3, BCL2
20	positive regulation of neuroblast proliferation	GO:002052	9.9	CTNNB1, VEGFC, NOTCH1, HIF1A
21	negative regulation of cell-matrix adhesion	GO:001953	9.8	CDKN2A, NF1, THBS1
22	cerebral cortex cell migration	GO:021795	9.8	EGFR, FGF13, NKX2-1
23	G-protein coupled receptor signaling pathway	GO:007186	9.7	GCG, VIP, GAST, SSTR5, SSTR4, SST
24	negative regulation of transcription from RNA polymerase II promoter	GO:000122	9.6	ISL1, NKX2-1, HES1, PDX1, NOTCH1, VHL
25	response to hypoxia	GO:001666	9.6	SMAD4, NF1, EGLN1, EGLN2, EGLN3, HIF1A
26	G1 phase of mitotic cell cycle	GO:000080	9.5	CDKN2C, CDKN1B, CDKN2A, CDK4
27	cellular response to hypoxia	GO:071456	9.2	HIF1AN, EGLN3, EGLN2, EGLN1, PTGS2, TP53
28	MAPK cascade	GO:000165	9.2	FGF13, MEN1, TGFA, NF1, EGFR
29	positive regulation of cell proliferation	GO:008284	9.1	NOTCH1, CDK4, CDKN1B, VEGFC, VIP, HES1
30	negative regulation of cell growth	GO:030308	9.1	SMAD4, TP53, CDKN2A, CDKN2C, BCL2, CDKN1B
31	cell cycle arrest	GO:007050	9.0	CDKN2A, TP53, TSC1, MEN1, TSC2, CDKN1B
32	G1/S transition of mitotic cell cycle	GO:000082	8.9	BCL2, CDKN2C, CDKN1B, CDKN2A, CDKN3, CDK4
33	negative regulation of transcription, DNA-dependent	GO:045892	8.9	HES1, NOTCH1, SMAD4, CTNNB1, TP53, MEN1
34	positive regulation of apoptotic process	GO:043065	8.8	TP53, RARB, PTGS2, MEN1, NEUROD1, NF1
35	positive regulation of transcription, DNA-dependent	GO:045893	8.5	SMAD4, NOTCH1, NKX2-1, NEUROD1, GHRH, TP53
36	negative regulation of apoptotic process	GO:043066	8.3	GCG, BCL2, NEUROD1, CDKN1B, ASCL1, CASP3
37	positive regulation of transcription from RNA polymerase II promoter	GO:045944	8.2	NOTCH1, NKX2-1, HIF1A, HES1, PDX1, SMAD4
38	response to drug	GO:042493	7.9	BCL2, THBS1, PTGS2, CTNNB1, SST, CDH1
39	signal transduction	GO:007165	7.7	MAP2K4, NTS, ESR1, HIF1A, GRP, GAST
40	negative regulation of cell proliferation	GO:008285	7.6	PTGS2, SSTR3, SSTR2, SSTR1, SST, MEN1

Molecular functions related to pancreatic endocrine tumors according to GeneDecks:

(show all 13)

id	Name	GO ID	Score	Top Affiliating Genes
1	somatostatin receptor activity	GO:004994	10.6	SSTR1, SSTR2, SSTR3, SSTR4, SSTR5
2	peptidyl-proline 4-dioxygenase activity	GO:031545	10.5	EGLN3, EGLN1, EGLN2
3	hormone activity	GO:005179	10.0	CALCA, GAST, SST, GCG, VIP, CHGB
4	neuropeptide hormone activity	GO:005184	9.9	VIP, NTS, NPY, GRP
5	cyclin-dependent protein kinase inhibitor activity	GO:004861	9.8	CASP3, CDKN2A, CDKN1B, CDKN2C
6	oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen	GO:016702	9.7	PTGS2, EGLN2, EGLN1, EGLN3, HIF1AN
7	double-stranded DNA binding	GO:003690	9.4	ASCL1, MEN1, CTNNB1, EGFR, POU3F4, NEUROD1
8	sequence-specific DNA binding	GO:043565	9.0	PDX1, HES1, SMAD4, HIF1A, NKX2-1, MEN1
9	protein phosphatase binding	GO:019903	8.9	CDH5, EGFR, CDKN1B, CDH1, CTNNB1
10	transcription factor binding	GO:008134	8.3	HIF1A, TP53, CTNNB1, HES1, NEUROD1, VHL
11	sequence-specific DNA binding transcription factor activity	GO:003700	8.0	MTA1, CDKN2A, CDX2, ASCL1, ISL1, ESR1
12	enzyme binding	GO:019899	7.2	HIF1A, EGFR, SLC18A2, NOTCH1, CTNNB1, TP53
13	protein binding	GO:005515	2.3	SSTR3, CEACAM1, S100A11, CHGB, BCL2, UTRN